Source:http://linkedlifedata.com/resource/pubmed/id/15351492
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2004-9-7
|
| pubmed:abstractText |
Live, cold-adapted, temperature-sensitive (ca/ts) Russian influenza A vaccines are prepared in eggs by a 6:2 gene reassortment of the ca/ts donor strain A/Leningrad/134/17/57 (H2N2) (Len/17) with a current wild-type (wt) influenza A strain contributing hemagglutinin (HA) and neuraminidase (NA) genes. However, egg-derived reassortant vaccines are potentially more problematic to manufacture in large quantities than vaccines from cell-based procedures. To compare egg- and cell culture-derived reassortant vaccines, we prepared in Madin Darby canine kidney (MDCK) cells two cloned, ca/ts reassortants (25M/1, 39E/2) derived from Len/17 and a wt reference strain A/New Caledonia/20/99 (H1N1) (NC/wt). Both 25M/1 and 39E/2 reassortants preserved the ca/ts phenotype and mutations described for internal genes of the A/Len/17 parent. When compared to a commercial, egg-derived ca/ts Russian A/17/NC/99/145 (H1N1) New Caledonia vaccine (NC/145), the MDCK-derived reassortant 39E/2 vaccine conferred similar levels of protection in ferrets challenged i.n. with 7 x 10(10) pfu of NC/wt. In a dose-ranging study, the protective vaccine dose for 50% of ferrets (PD50) was less than 1.2 x 10(4) pfu for the 25M/1 vaccine derived by recombination and amplification in MDCK cells. Clonal isolates of ca/ts influenza A/New Caledonia/20/99 (H1N1) obtained by recombination and amplification entirely in MDCK cells can be highly protective i.n. vaccines.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0168-1702
|
| pubmed:author |
pubmed-author:DiStefanoDanielD,
pubmed-author:JohnstonKimberlyK,
pubmed-author:KiselevaIrinaI,
pubmed-author:KraiouchkineNikolaiN,
pubmed-author:KwanWan-SangWS,
pubmed-author:MR GRG,
pubmed-author:MonteiroJuanitaJ,
pubmed-author:PalkerThomasT,
pubmed-author:PetrukhinLubaL,
pubmed-author:RubinBorisB,
pubmed-author:RudenkoLarisaL,
pubmed-author:ShawAlanA,
pubmed-author:SzymkowiakChristopherC,
pubmed-author:TonerTimothyT,
pubmed-author:WlochowskiJoanJ,
pubmed-author:YouilRimaR
|
| pubmed:issnType |
Print
|
| pubmed:volume |
105
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
183-94
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:15351492-Administration, Intranasal,
pubmed-meshheading:15351492-Animals,
pubmed-meshheading:15351492-Bronchoalveolar Lavage Fluid,
pubmed-meshheading:15351492-Cell Line,
pubmed-meshheading:15351492-Chick Embryo,
pubmed-meshheading:15351492-Disease Models, Animal,
pubmed-meshheading:15351492-Dogs,
pubmed-meshheading:15351492-Ferrets,
pubmed-meshheading:15351492-Hemagglutinin Glycoproteins, Influenza Virus,
pubmed-meshheading:15351492-Influenza A Virus, H1N1 Subtype,
pubmed-meshheading:15351492-Influenza A virus,
pubmed-meshheading:15351492-Influenza Vaccines,
pubmed-meshheading:15351492-Nasal Lavage Fluid,
pubmed-meshheading:15351492-Neuraminidase,
pubmed-meshheading:15351492-Orthomyxoviridae Infections,
pubmed-meshheading:15351492-Reassortant Viruses,
pubmed-meshheading:15351492-Vaccination,
pubmed-meshheading:15351492-Viral Plaque Assay,
pubmed-meshheading:15351492-Viral Proteins
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Protective efficacy of intranasal cold-adapted influenza A/New Caledonia/20/99 (H1N1) vaccines comprised of egg- or cell culture-derived reassortants.
|
| pubmed:affiliation |
Department of Virus and Cell Biology, Vaccine and Biologics Research, Merck Research Laboratories, Merck and Co., Inc., 770 Sumneytown Pike, WP16-101, West Point, PA 19486, USA. tom_palker@merck.com
|
| pubmed:publicationType |
Journal Article
|